These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32168068)

  • 1. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
    Jeurling S; Cappelli LC
    Curr Opin Rheumatol; 2020 May; 32(3):315-320. PubMed ID: 32168068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
    Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
    Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
    McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
    Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis.
    Cappelli LC; Kamal O; Jones M; Bingham CO; Shah AA
    Rheumatology (Oxford); 2024 May; 63(6):1518-1522. PubMed ID: 37647635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy.
    Jensen AK; Chatzidionysiou K; Torp CK; Sørensen AS; Tenstad HB; Schäfer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
    Biomed Pharmacother; 2022 Apr; 148():112687. PubMed ID: 35228067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.
    Roberts J; Smylie M; Walker J; Basappa NS; Chu Q; Kolinsky M; Lyddell C; Ye C
    Clin Rheumatol; 2019 May; 38(5):1513-1519. PubMed ID: 30701346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatologic immune checkpoint inhibitor-related adverse events.
    Defoe M; Bermas BL
    Curr Opin Rheumatol; 2023 May; 35(3):141-148. PubMed ID: 36912045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
    Ladouceur A; Barnetche T; Mouterde G; Tison A; Bitoun S; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Zysman M; Veillon R; Domblides C; Daste A; Gross-Goupil M; Sionneau B; Lefort F; Larroquette M; Richez C; Truchetet ME; Schaeverbeke T; Kostine M
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
    Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
    Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
    Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
    Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
    Williams SG; Mollaeian A; Katz JD; Gupta S
    Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
    Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
    Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy.
    Chan KK; Bass AR
    Rheum Dis Clin North Am; 2024 May; 50(2):337-357. PubMed ID: 38670731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
    Richter MD; Crowson C; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
    Arthritis Rheumatol; 2019 Mar; 71(3):468-475. PubMed ID: 30281202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.
    Subedi A; Williams SG; Yao L; Maharjan S; Strauss J; Sharon E; Thomas A; Apolo AB; Gourh P; Hasni SA; Gulley JL; Kaplan MJ; Katz JD; Gupta S
    JAMA Netw Open; 2020 Feb; 3(2):e200032. PubMed ID: 32101306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arthritis risk with immune checkpoint inhibitor therapy for cancer.
    Pundole X; Abdel-Wahab N; Suarez-Almazor ME
    Curr Opin Rheumatol; 2019 May; 31(3):293-299. PubMed ID: 30870217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
    Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
    Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
    Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
    J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-induced musculoskeletal manifestations.
    Angelopoulou F; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
    Rheumatol Int; 2021 Jan; 41(1):33-42. PubMed ID: 32743706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.